Evidence map›Paper›PMID 41453755›Full record

ArticleBrain pathology (Zurich, Switzerland)2026

Identification of novel FGFR2::TXLNB Fusion in a polymorphous low-grade neuroepithelial tumor of the young.

Sha-Sha Hu, Tian-Yuan Tan, Wei Yan, Bo Wang

Abstract readCase Reports
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sha-Sha HuDepartment of Pathology, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, China.
Tian-Yuan TanDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Wei YanMedical Laboratory Center, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, China.
Bo WangDepartment of Pathology, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, China.ORCID https://orcid.org/0009-0009-4597-4750

Funding

Hainan Province Science and Technology Special Fund ZDKJ2021040Hainan Province Science and Technology Special Fund ZDYF2021SHFZ247Hainan Province Science and Technology Special Fund ZDYF2022SHFZ040
6 · The paper itself

Abstract

We report a novel FGFR2::TXLNB fusion in a child with hippocampal PLNTY. This fusion likely drives tumorigenesis via homodimerization and activation of MAPK/PI3K pathways, expanding PLNTY's molecular spectrum and suggesting a potential therapeutic target.

Indexed as

Brain NeoplasmsNeoplasms, NeuroepithelialReceptor, Fibroblast Growth Factor, Type 2ChildFemaleHumansMaleOncogene Proteins, FusionFGFR2 protein, humanOncogene Proteins, FusionReceptor, Fibroblast Growth Factor, Type 2FGFR2::TXLNB fusionMAPKPI3K/mTORpolymorphous low‐grade neuroepithelial tumor of the young

Identifiers

PMID41453755
PMCPMC13051892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.